Stanozolol (Winstrol)

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Stanozolol (Winstrol)

A synthetic anabolic steroid that was FDA-approved for hereditary angioedema but is now discontinued.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved for hereditary angioedema, but discontinued in the US.

Stanozolol is a synthetic anabolic steroid developed in 1962 and approved by the FDA specifically for hereditary angioedema (HAE) to decrease the frequency and severity of attacks. It is rarely used today due to other available treatments. The FDA approved product was voluntarily withdrawn from the U.S. market in 2010.

Benefits reported in the imported source

• Prophylactic treatment to decrease frequency and severity of hereditary angioedema attacks.

Risks and limits

• Virilization in women
• Liver toxicity
• Cholestatic jaundice
• Androgenic effects

Source bottom line: Regulatory approval for hereditary angioedema, but discontinued in the U.S.; safer alternatives now available for this indication.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

No community description recorded. This entry has no final B-82 outcome record; it is not a researched-empty finding.

Pharmacokinetic context

Historical half-life estimate: 9 hours. Ruiz & Strain (eds.), Lowinson and Ruiz's Substance Abuse (2011), p.358 — oral tablet; the IM aqueous suspension form runs closer to 24 h Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Drugs@FDA: Winstrol (stanozolol) NDA 012885
• NCATS Inxight Drugs — Stanozolol
• Winstrol (Stanozolol) for Hereditary Angioedema (availability check 2026-10-15: source not retrieved; HTTP 403)